Publication:
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.

dc.contributor.authorJimeno, Rebeca
dc.contributor.authorMouron, Silvana Andrea
dc.contributor.authorSalgado, Roberto
dc.contributor.authorLoi, Sherene
dc.contributor.authorPérez-Mies, Belén
dc.contributor.authorSánchez-Bayona, Rodrigo
dc.contributor.authorManso, Luis
dc.contributor.authorMartínez, Mario
dc.contributor.authorGarrido-García, Ana
dc.contributor.authorSerrano-Pardo, Rosario
dc.contributor.authorColomer, Ramón
dc.contributor.authorQuintela Fandino, Miguel Angel
dc.contributor.authorcolomer
dc.contributor.funderMarie Curie Actionses_ES
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderCRIS Contra el Cancer Foundationes_ES
dc.date.accessioned2024-03-13T06:38:59Z
dc.date.available2024-03-13T06:38:59Z
dc.date.issued2023-04
dc.description.abstractPURPOSE Triple-negative breast cancer (TNBC) is characterized by large heterogeneity and relative lack of available targeted therapies. To find therapeutic strategies for distinct patients with TNBC, several approaches have been used for TNBC clustering, including recently immune and phosphoproteomic patterns. Based on 70-kDa ribosomal protein S6 kinase (P70S6K)-TNBC clustering, the current study explores the immune profiling in TNBC tumors. METHODS Stromal tumor-infiltrating lymphocytes (sTILs) were evaluated in human TNBC tumor samples. Furthermore, immunohistochemistry staining for CD8, CD4, Foxp3, and CD20 was performed in tissue microarrays (TMA) sections. RESULTS Histological analysis showed decreased sTILs, CD20+ cells, and CD8+/CD4+ ratio in high phosphorylated P70S6K (p-P70S6K) tumors. Moreover, p-P70S6K score was directly correlated with CD4+ and Foxp3+ T cells, while it was inversely correlated with CD8+/CD4+ and CD8+/Foxp3+ ratios. CONCLUSION sTIL infiltration and lymphocyte profiling vary in the context of hyperactivation of P70S6K in TNBC tumors.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipRJ is a recipient of the following grants: Eva Plaza/CNIO Friends Fellowship and Marie Sklodowska-Curie Individual Fellow-ship. The project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 893597. RC is a recipient of the ISCIII grants: PI17/01865 and PI20/01458. MQF is a recipient of the following Grants: AES-PI19/00454 funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) and B2017/BMD3733 (Immunothercan-CM)-Call for Coordinated Research Groups from Madrid Region-Madrid Regional Government-ERDF funds. The study was also funded by CRIS Contra el Cancer Foundation.es_ES
dc.format.number4es_ES
dc.format.page1124es_ES
dc.format.volume25es_ES
dc.identifier.citationClin Transl Oncol . 2023 ;25(4):1124-1131.es_ES
dc.identifier.doi10.1007/s12094-022-03006-3es_ES
dc.identifier.e-issn1699-3055es_ES
dc.identifier.journalClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexicoes_ES
dc.identifier.pubmedID36508123es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18920
dc.language.isoenges_ES
dc.publisherSpringer
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI17/01865es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI20/01458es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19/00454es_ES
dc.relation.publisherversionhttps://doi.org/10.1007/s12094-022-03006-3.es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer de Mamaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshLymphocytes, Tumor-Infiltratinges_ES
dc.subject.meshTriple Negative Breast Neoplasmses_ES
dc.subject.meshHumanses_ES
dc.subject.meshPrognosises_ES
dc.subject.meshRibosomal Protein S6 Kinases, 70-kDaes_ES
dc.subject.meshForkhead Transcription Factorses_ES
dc.subject.meshBiomarkers, Tumores_ES
dc.titleTumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication2b24dcc5-53ed-436d-9e43-15b749624076
relation.isAuthorOfPublicationf95b0d37-00ac-4524-a4b2-c2c988784d1f
relation.isAuthorOfPublication.latestForDiscovery2b24dcc5-53ed-436d-9e43-15b749624076
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication8d558850-2ef2-4d1e-b0e1-4e5591ab6288
relation.isPublisherOfPublication.latestForDiscovery8d558850-2ef2-4d1e-b0e1-4e5591ab6288

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
TumorP70S6Khyperactivationisinversely_2023.pdf
Size:
1.4 MB
Format:
Adobe Portable Document Format
Description:
Artículo principal